Atlas Trials

Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis

Clinical trial NCT02474069 · COMPLETED

Trial details

NCT number
NCT02474069
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Moderate to Severe Plaque-type Psoriasis
Start date
2015-02-08
Primary completion
2016-09-15
Enrollment
772

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.